AIMP2

Across TCGA pan-cancer cohorts, AIMP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AIMP2 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher AIMP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated AIMP2 expression acts as an unfavorable survival marker.

LSCC, LUAD, and CCRCC are the cancer types where AIMP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	III,IV	0.476	0.834	.033	6	view →
LUAD	DFS	Median	All	0.862	0.941	.021	5	view →
CCRCC	DFS	Quartile	All	0.611	0.873	.016	4	view →
PDAC	OS	Tertile	All	0.765	0.927	.023	4	view →
GBM	OS	Median	All	0.265	0.522	.002	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AIMP2–LSCC (OS)

Open the LSCC breakdown →